and East Hanover, NJ GRAPHICAL ABSTRACT Background: Hyperactivity of the IL-23/IL-17 axis is central to plaque psoriasis pathogenesis. Secukinumab, a fully human mAb that selectively inhibits IL-17A, is approved for treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. Secukinumab improves the complete spectrum of psoriasis manifestations, with durable clinical responses beyond 5 years From a the
of treatment. In the feed-forward model of plaque chronicity, IL-17A has been hypothesized as the key driver of pathogenic gene expression by lesional keratinocytes, but in vivo evidence in human subjects is lacking. Methods: We performed a randomized, double-blind, placebocontrolled study (NCT01537432) of patients receiving secukinumab at the clinically approved dose up to 12 weeks. We then correlated plaque and nonlesional skin transcriptomic profiles with histopathologic and clinical measures of efficacy. Results: After 12 weeks of treatment, secukinumab reversed plaque histopathology in the majority of patients and modulated thousands of transcripts. Suppression of the IL-23/IL-17 axis by secukinumab was evident at week 1 and continued through week 12, including reductions in levels of the upstream cytokine IL-23, the drug target IL-17A, and downstream targets, including b-defensin 2. Suppression of the IL-23/IL-17 axis by secukinumab at week 4 was associated with clinical and histologic responses at week 12. Secukinumab did not affect ex vivo T-cell activation, which is consistent with its favorable long-term safety profile. Conclusion: Our data suggest that IL-17A is the critical node within the multidimensional pathogenic immune circuits that maintain psoriasis plaques and that early reduction of IL-17Adependent feed-forward transcripts synthesized by hyperplastic keratinocytes favors plaque resolution. (J Allergy Clin Immunol 2019;144:750-63.)
Key words: Secukinumab, IL-17A, plaque psoriasis, transcriptomics Psoriasis is a chronic autoimmune disease characterized by erythematous, scaly, and hyperkeratotic skin plaques that can cover the majority of the body, conferring significant stress and social stigma. 1 The global burden of psoriasis is substantial because of its presence in 1% to 3% of Western populations and a variety of systemic comorbidities. [2] [3] [4] The cause of psoriasis is multifactorial, with genetic and environmental influences. Mounting evidence indicates that dermal inflammation drives keratinocyte (KC) hyperplasia and skin remodeling in plaques through local hyperactivation of pathways that normally maintain skin barrier immunity. 5, 6 In addition, plaques exhibit characteristic alterations in vasculature, nerves, and melanocytes. [7] [8] [9] [10] Basic research and several clinical trials have suggested a dominant pathogenic role in patients with psoriasis for IL-17A, 11 one of 6 human IL-17 family cytokines (designated IL-17A-F). 12 IL-17A orchestrates skin and mucosal immunity, and its upregulation in patients with psoriasis is implicated in plaque histopathology. 13 It is hypothesized that KC stress, dendritic cell (DC) activation, and autoreactive skin-homing T cells against antimicrobial peptides, such as cathelicidin, coordinately initiate plaques. 14 In current models activation of resident skin cells produces proinflammatory IFN-a, IFN-g, and TNF-a, which activate myeloid DCs to produce IL-12 and IL-23. Although IL-12 triggers proinflammatory T H 1 pathways, IL-23 attracts, expands, and polarizes T H 17 cells and other leukocytes to secrete IL-17A and other cytokines, including IL-17F and IL-26. IL-17A signals through IL-17 receptors, with distinct effects in different cell types. For example, IL-17A autoactivates its own synthesis in T cells, induces proinflammatory IL-6 and IL-8/CXCL8 in the dermis, and promotes synthesis of mitogenic factors, cytokines, chemokines, and antimicrobial proteins, leading to KC hyperplasia. 15 The mechanism by which KC hyperplasia amplifies plaque and possibly systemic inflammation has been put forth in a hypothetical ''feed-forward'' model. In it, T H 17-derived IL-17A and IL-17F induce massive overproduction of inflammatory products, such as IL-17C, IL-36, IL-19, CCL20, CXCL chemokines, and S100 proteins, in psoriatic KCs, in turn altering resident skin cell homeostasis and further attracting activated leukocyte subsets to maintain plaques. 7, 16, 17 KC-produced IL-17C is capable of further amplification of this immune circuit by activating T H 17 cells to secrete more IL-17A. 18 Support for systemic feed-forward inflammation originated from studies in transgenic mice: misexpressing inflammatory products in KCs led to increases in vascular inflammation, arthritis, and soluble mediators in the circulation. 19, 20 Cultured human skin models also support the model: a role for KC differentiation and connective tissue in the response to IL-17A is evidenced by the approximately 10 times increase in the number of IL-17A-induced genes in stratified human skin cultures compared with monolayer KC cultures, 21 in part because of higher levels of the transcription factors CCAAT enhancerbinding protein (C/EBP) b or C/EBPd, which mediate IL-17induced signals in differentiated spinous and granular KC layers. 13 Finally, synergistic activity of IL-17A with nuclear factor k-light-chain enhancer of activated B cells (NF-kB)-activating factors, such as TNF and IL-1, can occur through linked NF-kB and C/EBP binding sites in the promoters of many IL-17-responsive genes. 22, 23 Nevertheless, there is scant evidence to support the feed-forward model in human psoriasis. The availability of therapeutics that target IL-17A allowed us to investigate the extent to which the efficacy of these agents is associated with reduction in T H 17 T-cell activation responses versus KC feedforward responses.
Secukinumab (Cosentyx; Novartis, Basel, Switzerland) is a fully human mAb that selectively inhibits IL-17A and demonstrates long-lasting efficacy in the complete spectrum of tissues affected in patients with psoriasis, including nails, scalp, palms, soles, and joints (in patients with psoriatic arthritis). [24] [25] [26] [27] Secukinumab and other agents that target the IL-23/IL-17 axis are increasingly selected as front-line therapy for moderate-to-severe psoriasis; however, the mechanisms by which IL-17A blockade disrupts plaque immune circuits and cellular responses when used at a clinically relevant dose, schedule, and typical evaluation end point of 12 to 16 weeks after initiation of therapy are unknown. To investigate these mechanisms, patients with psoriasis were treated with 300 mg of subcutaneous secukinumab or placebo over 12 weeks, followed by an open-label period with secukinumab given up to 52 weeks, and skin biopsy specimens were analyzed for histopathologic and transcriptomic changes with concurrent clinical assessments. Here we report results from the placebo-controlled period of the study up to week 12.
METHODS
This study (NCT01537432) was a 2-part, exploratory, phase 2, randomized, double-blind, placebo-controlled study of patients with moderate-to-severe psoriasis. Patients 18 years or older with inadequately controlled psoriasis for more than 6 months were randomized 2:1 to receive secukinumab or placebo (see Fig E1 in this article's Online Repository at www.jacionline.org). Twelve US clinical sites enrolled 36 patients (see Table E1 in this article's Online Repository at www.jacionline.org). In part 1 patients received 300 mg of subcutaneous secukinumab or placebo for 12 weeks; in part 2 all patients received 300 mg of subcutaneous secukinumab to week 52 (manuscript in preparation).
The primary objective was to evaluate the proportion of patients achieving histologic disease reversal at week 12 with secukinumab compared with placebo based on an established histologic scoring system. Clinical efficacy was correlated with histopathologic features, cell counts by using immunohistochemistry (IHC), and mRNA transcript profiles of lesional (LS) plaque and nonlesional (NL) skin biopsy specimens collected at baseline, week 1 (n 5 13 enrolled patients) or week 4 (n 5 23 enrolled patients), and weeks 12 and 52. Whole-biopsy transcript profiles were generated on Affymetrix gene chips (Human Genome U133 Plus 2.0; Affymetrix, Santa Clara, Calif) and a custom psoriasis-relevant 314-gene nanoString panel (listed in the Methods section in this article's Online Repository at www.jacionline.org). Data from each platform were compared to ensure accurate assessment and then analyzed: (1) by comparison with published data sets, including our metaanalysis derived-3 (MAD-3) meta-transcriptome generated by aggregating normalized data from 3 prior studies that used the same Affymetrix platform as this study 28 ; (2) by using Gene Set Variation Analysis (GSVA) 29 ; 3) by means of hierarchical clustering (Tibco Spotfire); (4) by gene, with reference to gene families and pathways with known functions in skin biology and disease; and (5) between responders and nonresponders. The effect of secukinumab on ex vivo T-cell activation was investigated at baseline and week 4. Additional methods have been described elsewhere, 30, 31 and a further description of methods and results can be found in the Methods section in this article's Online Repository. Affymetrix microarray data can be accessed at the National Center for Biotechnology Information's database of Genotypes and Phenotypes under accession number phs001688.v1.p1.
RESULTS

Secukinumab induces clinical and histologic resolution of psoriasis
Study design and patients' dispositions are shown in Fig E1 and Table E2 in this article's Online Repository at www.jacionline. org. Patients' characteristics were comparable between groups, except for a slight male preponderance in the secukinumab group (see Table E3 in this article's Online Repository at www. jacionline.org).
The primary objective of the study was met: 13 (56.5%) of 23 secukinumab-treated patients versus 0 (0.0%) of 12 placebo-treated patients achieved histologic disease reversal (''excellent improvement''/histology score 13; criteria are shown in Table E4 in this article's Online Repository at www.jacionline.org) by week 12 (P < .001, 1-sided Fisher exact test; see Table E5 in this article's Online Repository at www.jacionline.org). 25 By clinical measures, 15 (62.5%) of 24 secukinumab-treated patients achieved 75% or greater improvement in their baseline Psoriasis Area and Severity Index (PASI) score (ie, PASI75) after 12 weeks of secukinumab compared with 0 (0%) of 12 in the placebo-treated group (see Table E6 in this article's Online Repository at www.jacionline. org). Onset of PASI responses were comparable with published studies, with a mean reduction of baseline PASI scores of 78% at 12 weeks (Fig 1, A) . 25 Among secukinumab-treated patients, there was a significant correlation (Spearman r 5 20.77, P < .001) between percentage of PASI score reduction and LS skin histologic improvement score at week 12 (Fig 1, B) . Patients whose LS skin histology did not completely resolve by week 12 were designated as nonresponders with partial (histology score 5 11 or 12, n 5 5) or no (histology score 5 0 or 21, n 5 3) improvement. The safety and tolerability of secukinumab were consistent with results of previous studies (see Table E7 in this article's Online Repository at www.jacionline.org). 25 Because efalizumab, a psoriasis therapy that reduces T-cell activation, was withdrawn from the market in 2009 because of serious infections such as progressive multifocal leukoencephalopathy, 32 we tested whether secukinumab affected T-cell activation. Consistent with the favorable long-term safety profile of secukinumab observed in large studies, there were no significant differences in ex vivo Tcell activation at baseline or week 4 with secukinumab versus placebo (P > .05 for all, see Table E8 in this article's Online Repository at www.jacionline.org).
Progressive molecular resolution of the psoriasis transcriptome by secukinumab
We next investigated secukinumab-induced changes in the LS skin transcriptome. Transcripts were considered differentially expressed genes (DEGs) if the P value corrected for false discovery rate (q value) was less than .05, and fold change (FC) was 2 or greater or 22 or less (ie, >62), unless otherwise noted. Our cohort's psoriasis transcriptome (PT) was defined as DEGs between baseline LS and NL biopsy specimens and included 2971 probe sets (1969 genes with unique identifiers) identified by Affymetrix. The PTs were highly similar between treatment groups and, after comparison of the top 20 LSupregulated genes, to previously published PT meta-analyses, including our MAD-3 PTs (Table I and toward baseline NL specimen levels. Among probe sets affected by secukinumab at week 12, 47% also showed significant changes at week 4, but only 1 gene (ANKRD13C) met the criterion of a q value of less than 0.05 criteria at week 1. By relaxing the FC greater than 61.5 (and q < 0.2 only at week 1), 5 probe sets were changed in the placebo group versus 103 probe sets in the secukinumab group at week 1, 74 of which were among larger groups of genes regulated by secukinumab at weeks 4 and 12 (Fig 2, B and C) . By week 12, secukinumab induced approximately 80% mean normalization of baseline LS gene expression and greater than 90% mean normalization in MAD-3 PT genes (see Fig E4 in this article's Online Repository at www.jacionline.org). By using nanoString profiling, 204 genes had at least 1 corresponding Affymetrix probe set measurement, whereas the remaining 110 genes of the nanoString panel were not detected at robust levels by using the Affymetrix platform (list provided in the Methods section in this article's Online Repository). A heat map of nanoString data also shows that secukinumab converted the LS gene profile toward NL specimen data (see Fig E5 in this article's Online Repository at www.jacionline. org). There were 38 DEGs in LS specimens with secukinumab at week 1 that were among larger groups of DEGs at weeks 4 and 12 (Fig 2, B) . Furthermore, there was a positive correlation of log 2 FCs (Spearman r 5 0.93, P < .05) among the 145 genes (247 Affymetrix probe sets, with some nanoString genes having > _2 corresponding Affymetrix probe sets), showing significant differences (q < 0.05) in LS specimens at week 12 versus baseline values on both platforms (Fig 2,  D) . Strikingly, 18 of the 20 genes most highly downregulated by secukinumab at week 12 were among the top 20 genes upregulated in baseline LS specimens, with similar FCs (Table I) .
Our data confirm resolution of the PT by secukinumab by using independent transcript profiling methods and suggest that our cohort reflects the larger population of patients with plaque psoriasis.
Secukinumab normalizes transcripts and pathway signatures that drive plaque formation in multiple cell types
To investigate the biological significance of secukinumabinduced changes in the transcriptome, we integrated GSVA and hierarchical clustering of Affymetrix data with gene-level queries of both data sets.
With GSVA, we quantified in our cohort the behavior of more than 300 preselected curated gene sets representing established skin biology and disease pathways (Table II) . 6, 13, 21, 28, [35] [36] [37] [38] [39] [40] [41] [42] The extent to which levels of a transcript or set of transcripts (ie, a pathway signature, represented in GSVA by a pathway score) approaches baseline NL levels during treatment is a measure of improvement, with 100% improvement corresponding to baseline NL levels in treated LS specimens. Secukinumab improved PT genes; for example, MAD-3 PT LS-upregulated genes were improved 91% by secukinumab at week 12. Consistent with IHC of biopsy specimens, GSVA showed that secukinumab improved pathway scores of gene sets representing T cells and various myeloid-derived cells (Table II) . Statistically significant (q < 0.05) changes in IL-17-dependent pathway scores were seen at weeks 1 through 12 compared with baseline values (Table II) .
Hierarchical clustering of all week 12 secukinumabresponsive genes (FC > 62) revealed clusters with similar temporal profiles; we designated a subset of clusters with representative profiles by the letters A through K (Fig 3) . The primary division of the dendrogram shows rapid onset of secukinumab action: the vast majority of DEGs begin to normalize by week 1, with greater FCs through weeks 4 and 12. Several DEGs with the highest baseline FCs, including defensin b 4A (DEFB4A), lipocalin 2 (LCN2), and several S100 genes, coclustered, and additional clusters revealed early and delayed response genes distinguished by whether normalization of transcripts began at week 1 or was delayed until week 4. Additional clusters enriched for immunoglobulin genes (ie, B or plasma cells) and fibroblast/extracellular matrix genes were increased in baseline LS specimens but increased further by week 12 (Fig 3) . Among the 110 nanoString genes not detected at robust levels on the Affymetrix platform, many are important low-abundance transcripts that were not included in previous Affymetrix-based profiles of psoriasis (Fig 4 and see the Methods section in this article's Online Repository). Secukinumab reduced its target, IL-17A, 6.6 times (fold) in LS specimens by week 12, as well as the T H 17 products IL-17F (6.4 times) and IL-26 (3.6 times; Fig  4, A) . Upstream of IL-17, secukinumab reduced both IL-23 subunits (IL-23A/p19 and IL-12B/p40) 2.3 to 3.5 times and IL-23 receptor subunits approximately 2 times (Fig 4, B) . Selected changes at week 12 measured by using nanoString that support the feed-forward concept are illustrated in Fig 4, C. Additional transcript changes grouped by cell types and pathways are presented in Figs E6 to E37 in this article's Online Repository at www.jacionline.org.
Analysis of secukinumab responders versus nonresponders
We investigated whether secukinumab-associated increases in matrix and immunoglobulin transcripts occur with other biologics. Although increases in some matrix genes in cluster K, such as collagen type I a 2 chain (COL1A2) and fibronectin 1 (FN1), were also seen in etanercept PASI75 responders, 43 increases in most immunoglobulin probe sets were specifically seen in secukinumab responders (see Fig E38 in this article's Online Repository at www.jacionline.org).
To identify early transcripts associated with disease resolution, we modeled Affymetrix data sets using logistic regression.
Although none of the top 10 regulated transcripts at week 1 met significance criteria because of the small number of nonresponders biopsied, modulation of IL36G at week 4 was most associated with histologic response at week 12 (P 5 .067, see Fig E39 in this article's Online Repository at www.jacionline. org and data not shown). Similarly, among nanoString genes with FCs of greater than 62 at weeks 4 and 12 in week 12 responders based on either histologic or PASI75 criteria, the majority of transcripts showed the same directional FC at week 1, with IL8/CXCL8 and IL19 showing the largest reductions at week 1 (see Figs E40 and E41 in this article's Online Repository at www.jacionline.org). Surprisingly, there was only partial overlap between responder versus nonresponder DEGs associated with week 12 PASI75 versus the histologic response ( Fig 5, A) . Because the LS biopsy improvement score is based solely on epidermal features (see Table E4 ), many KC differentiation and immune activation genes associate with histologic response, whereas PASI75 response genes included KC growth, immune signaling, and dermal matrix genes (Fig 5, A) . DEGs by either criterion included IL17A and IL36G. Week 4 responder changes include reduced cell proliferation (marker of proliferation Ki-67 [MKI67]) and KC growth factors (amphiregulin [AREG] and TGFA), with variable modulation of IL17A and its targets (DEFB4A, LCN2, and S100s). Fig 5, B and C, shows that although both responders and nonresponders had reduced IL17A (and IL17F) expression by week 4, by week 12, responders but not nonresponders had further reductions in both transcripts and all 3 IL36 genes (q < 0.05) that paralleled reductions in IL17C expression. These data suggest that early PT improvements and week 12 outcomes depend more on early reductions in KC-derived proinflammatory feed-forward 
DISCUSSION
Here we report plaque histopathology and transcriptome profiles from patients with psoriasis administered secukinumab, the first IL-17A antagonist approved for psoriasis, at the dose and schedule approved for clinical use. Key strengths of this study include (1) adequate power to reveal time-dependent and statistically significant group-level transcriptome profiles with 25 suggesting that our results are broadly applicable to patients with plaque psoriasis who are candidates for biologic therapies. The majority of patients given secukinumab achieved PASI75 (and PASI90, see Table E6 ) and ''excellent improvement'' on their LS specimen histologic scores by week 12, with good correlation between clinical and histologic end points.
Our data reveal new insights into early events after IL-17A inhibition by secukinumab. As early as 1 week, secukinumab caused substantial and progressive changes in hundreds of LS transcripts accompanied by reduced inflammatory infiltrates, epidermal thickness, and mitotic activity. Reductions in critical downstream targets of IL-17A in the skin, including the antimicrobial peptides DEFB4A/b-defensin 2 and the S100 family were anticipated given prior transcript profiling studies of psoriasis. Although GSVA revealed changes in many cell typespecific and inflammatory genes and pathways with known significance to skin biology and psoriasis, the functions of many secukinumab-modulated genes remain unknown.
Although the majority of PT genes responded to secukinumab at week 1 (Fig 3) , hierarchical clustering identified delayedresponse clusters enriched for interferon and innate immune response genes, suggesting a stereotyped temporal hierarchy of molecular events in response to IL-17A blockade. We also identified clusters enriched for immunoglobulin genes and fibroblast/ dermal matrix products whose baseline increase in LS specimens FIG 3 . Hierarchical clustering of secukinumab (SEC) response probe sets. The left heat map shows hierarchical clustering of all Affymetrix probe sets (2829) with greater than 62 FC in LS specimens at week 12 versus baseline (BL) LS specimens with secukinumab. Representative lettered clusters with early response at 1 week versus delayed response at 4 weeks versus continuous increase with secukinumab (except cluster J, which shows a decrease at week 1 but increases at weeks 4 and 12), are shown in heat maps in each column, with indicated genes listed at the right of each row. Clinical (PASI75, left) and histologic (right) end points were considered. A Venn diagram shows the number of DEGs shared or unique to PASI75 or histologic responders with representative pathways. Genes colored red or blue increase or decrease, respectively, compared with baseline LS specimens. B and C, Mean 6 SEM log 2 expression for LS specimens in responders (solid line) and nonresponders (dotted line) for selected genes. Clinical (Fig 5, B) and histologic (Fig 5, C) responses were considered. Comparisons at week 12: *P < .05 and **q < 0.05. and further increase by week 12 with secukinumab suggest progressive skin remodeling with plaque resolution that appears distinct from the effects of etanercept, an anti-TNF-a biologic with a distinct mechanism of action.
We also identified changes in genes that regulate peripheral lipid metabolism (see Fig E35) . Although these genes have been previously identified in PTs, 44, 45 changes with secukinumab predict cleared plaque skin should have a markedly improved ability to metabolize circulating lipids and possibly lower long-term risk of comorbid cardiovascular and metabolic complications. 46 There are several reports on the effects of immune-modulating therapies on psoriasis histopathology, but few have correlated clinical and histologic changes with transcriptomic changes at clinically relevant and approved drug doses. One week after administration of cyclosporine, psoriatic LS specimens showed reductions in KC hyperplasia, mitoses, lymphocytic and perivascular mononuclear infiltrates, and antigen-presenting cells and complete clearance of neutrophils. 47 Although we did not quantify neutrophils, secukinumab response was associated with reductions in neutrophil-enriched transcripts (lactotransferrin [LTF] and proteinase 3 [PRTN3]) and chemoattractants (CXCL8/IL8; Fig 5, A, and see Fig E24) , which is consistent with neutrophil clearance being an early event in plaque resolution by secukinumab. 48 One week after initiation of etanercept, LS epidermis in responders was thinned by approximately 20%, and mitotic activity reduced be greater than 50%; numbers of CD3 1 T cells, CD11c 1 myeloid DCs, and CD163 1 macrophages decreased at 2 weeks, whereas numbers of CD83 1 and DC lysosomeassociated membrane glycoprotein-positive DCs were reduced at 1 and 2 weeks (neutrophils were not examined). 35 The study implicated reduced DC recruitment, activation, and maturation in early responses of LS specimens to TNF-a blockade while also providing evidence for an upstream role of IL-17 in psoriasis pathogenesis. 35 Newer biologics that target IL-12 and IL-23 (ustekinumab) or IL-23 alone (risankizumab, guselkumab, and tildrakizumab) and have superior efficacy to anti-TNF-a agents but limited transcript profiling data have been reported. 49, 50 Biopsy transcript profiles from patients given ixekizumab or brodalumab, which target IL-17A or its receptor, respectively, have been reported 31,51 : Krueger et al 31 showed that increasing doses of ixekizumab improved plaque histopathology and PTs at 2 and 6 weeks after dosing, but these doses were not pursued in later registration trials (or in the clinic). In the study by Russell et al, 51 increasing doses of brodalumab reduced levels of IL-17s (A, C, and F) and IL-17 target genes in LS specimens that partially correlated with drug exposures. Although LS biopsy specimens were analyzed from only 4 patients 1 week after initiation of brodalumab, our study analyzed a larger number of patients at week 1 to derive treatment group level and responder/nonresponder transcript profiles, including low-abundance transcripts not previously measured. 31, 51 The feed-forward model has 2 key elements. First, IL-17A, in synergy with NF-kB-activating cytokines, such as TNF or IL-1b, induces many inflammatory products in KCs, including IL-17C, the IL-36 family, CXCL8/IL-8, IL-19, and numerous chemokines and antimicrobial proteins. Second, IL-17A-induced KC-derived products act in an autocrine fashion to further drive KC hyperplasia and attract inflammatory infiltrates that typify psoriatic plaques. Our responder/nonresponder analysis provides critical human data supporting the feed-forward concept and further suggests a role for IL36B and IL36G in chronic plaques. As members of the IL-1 family, IL-36 family molecules also activate NF-kB signaling and thus are poised to synergize with KC signaling pathways driven by IL-17. 52, 53 Of note, inhibition of the IL-36 pathway was recently shown to be efficacious in patients with pustular psoriasis. 54 IL-19 also showed early downregulation by secukinumab in responders, just missing significance (q 5 0.06) in our responder/ nonresponder comparison (not shown). Although IL-19 has mitogenic activity on KCs, 55 we also identified early modulation of the mitogenic epidermal growth factor family members AREG and TGFA in secukinumab responders. Finally, early reductions in expression of IL-17A target genes induced in cultured human skin models correlated with clinical and histologic responses at week 12. Hence our data suggest that early and robust downregulation of feed-forward genes after IL-17A neutralization by secukinumab, rather than reduction of T H 17-dependent IL-17A synthesis, portends successful outcomes. That levels of upstream IL-23 and related IL-17F were reduced indicates that secukinumab also disrupts IL-17A-dependent feedback mechanisms that drive plaque chronicity. We speculate that when IL-17A is bound by secukinumab during active treatment, reduced IL-17A production by T cells might be a consequence of reduced KC-derived IL-17C acting on T cells rather than from reductions in IL-17A and IL-17F per se.
Our study had several limitations. First, week 1 and week 4 biopsy specimens were collected from different patients, precluding a complete biopsy time course in each patient. Second, some important low-abundance transcripts might not have been measured because of biased selection of genes for the nanoString panel. Finally, there was no measurement of drug concentrations, preventing correlation of drug exposures with various pharmacodynamic parameters. Nevertheless, these limitations do not alter the statistical robustness, biological interpretation, or potential clinical implications of our study. Future analyses will examine clinical, histologic, and transcriptomic changes with prolonged IL-17A blockade to understand how secukinumab achieves sustained clear skin in the vast majority of patients.
